Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06070012 · ClinicalTrials.gov registry record · Phase 2
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
A Phase 2 study of Uveal Melanoma, sponsored by Diwakar Davar.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 3
- Study locations
NCT06070012 is a Phase 2 study of Uveal Melanoma that is actively recruiting participants, run by Diwakar Davar. The registered enrollment target is 44 participants, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06070012, a Phase 2 study of Uveal Melanoma, is actively recruiting participants, sponsored by Diwakar Davar.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
Conditions Studied
Interventions
- DRUG Tebentafusp
Study Locations (3)
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06070012
The ClinicalTrials.gov registry entry for NCT06070012 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (69% lower). The listed sponsor is Diwakar Davar, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Tebentafusp is the first listed.
NCT06070012 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, District of Columbia, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06070012 about?
NCT06070012 is a clinical study titled "Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma". This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
What is the current status of trial NCT06070012?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2025-08-18. Estimated completion is 2030-09-30.
What conditions does trial NCT06070012 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT06070012?
The interventions under investigation include: Tebentafusp (DRUG).
Who is sponsoring clinical trial NCT06070012?
This trial is sponsored by Diwakar Davar, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06070012 being conducted?
This trial has 3 study locations across Colorado, District of Columbia, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.